Nobel Signs Licensing Deal With SRI For Endometriosis Drug
This article was originally published in PharmAsia News
Nobel Pharma Japan has entered into a license agreement with SRI International regarding the domestic clinical trials and development of SRI’s endometriosis drug candidate SR16234.
You may also be interested in...
Interested parties have been consulted, workshop findings noted and online surveys completed; the drafting of Germany’s digital health strategy is now underway.
The hard going could get even tougher as a funding crunch continues for China’s biotech sector, which is being hit by a paradox that could see more pain ahead, leading investors to take the pulse of the sector as the Year of the Rabbit starts.
The CEO of one the global top-five CROs points out a larger opportunity in decentralized trials that might be a “game changer” in the global pharma industry over the next five years. He also refers to the need to accept new technologies by both clinical trial sites and regulators.